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Vascular complications of diabetes mellitus involve abnormal (diminished) 
vascular responses to vasodilators. One contributing factor to the development of 
diabetic abnormality could be an impairment of the cyclic AMP (cAMP) response to 
CGRP, however, until now, this has not been reported. Regulation of apoptosis and 
proliferation in vascular smooth muscle cells (VSMCs) is thought to involve, at least in 
part, the cyclic GMP (cGMP)/protein kinase G (PKG) signaling pathway. However, 
previous reports concerning the role of cGMP/PKG in VSMC apoptosis and 
proliferation are contradictory and incomplete. 
The present study shows that exposure of early-passaged rat aortic VSMCs to 
hyperglycemic conditions severely diminished cAMP responses to CGRP. Even basal 
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levels of cAMP were significantly lowered by 6 h exposure to high glucose (40 mM). 
The data indicate that phenotypically-normal VSMCs are sensitive to the damaging 
effects of high glucose, resulting in severely diminished cAMP response to CGRR 
Because CGRP is an important endogenous vasodilator, the impaired cAMP response to 
CGRP following hyperglycemia may contribute to certain vascular complications of 
diabetes. 
Previous studies from our laboratory suggested that basal cGMP level is essential 
for preventing spontaneous onset of apoptosis in many neural cells, pancreatic islets, 
ovarian cancer cells and uterine epithelial cells. In the present study, inhibition of basal 
PKG activity using DT-2 and DT-3, two newly-developed highly-specific inhibitors of 
PKG, did not alter apoptosis in VSMCs (with serum). However, DT-2 and DT-3 
enhanced the serum-deprivation-induced apoptosis, suggesting that, in VSMCs, basal 
cGMP/PKG activation is not involved in preventing spontaneous apoptosis under 
normal culturing conditions. Only during a stressful condition (e.g. serum deprivation) 
was the anti-apoptotic (partially protective) effects of PKG observed. 
The present study also showed that high levels of the NO donor SNAP (500 |LIM) 
causes apoptosis in early-passaged/phenotypically-normal VSMCs and that 
pre-incubated with atrial natriuretic peptide (ANP) to activate the cGMP/PKG pathway 
prior to exposure to high/toxic levels of NO could completely prevented the apoptosis. 
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The data suggest that, under certain stressful conditions, PKG does have a protective 
role, helping to limit the extent of stress-induced apoptosis in VSMCs. 
In the present study, passage 0 (phenotypically normal) VSMCs were used and 
involvement of basal PKG activity on proliferation rate was determined. Proliferation 
rates were measured by 1) increase in number of cells after 3 days, 2) MTT 
measurement after 3 days in culture, and 3) BrdU incorporation (i.e. de novo synthesis 
of DNA) over 4 h. Both DT-2 and DT-3 dramatically reduced proliferation rates (cell 
count and MTT measurements) to only 30% of control rates and reduced de novo DNA 
synthesis rates (BrdU measurement) to half of control levels, suggesting that basal PKG 
activity is necessary for serum-factor-induced stimulation of cell proliferation in 
phenotypically-normal VSMCs. 
In rat bone marrow stromal stem cells (rMSCs), inhibition of basal PKG activity 
did not affect apoptosis, either with or without serum. Thus, PKG may not be playing a 
critical role in preventing spontaneous onset of apoptosis in these cells. However, both 
DT-2 and DT-3 dramatically reduced cell proliferation rate to less than half of control 
levels, suggesting that basal PKG activity (likely the PKG-Ia isoform, the isoform that 





















此外，本硏究顕示NO供體一硝基氫氧酸（SNAP, 500 |LIM)處理誘導VSMCS 
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Chapter 1. General Introduction 
Cardiovascular disease is the leading cause of death among patients with 
diabetes, and diabetes is recognized as an important risk factor for the development 
of atherosclerosis and vascular complications. The abnormal growth of vascular 
tissue likely involves an imbalance between apoptotic cell death (apoptosis) and 
proliferation of the vascular smooth muscle cells (VSMCs) in the walls of arteries 
and arterioles. CGRP is thought to inhibit the development of atherosclerosis by 
inhibiting the proliferation of VSMCs (Li et al.，1997). Also, CGRP is likely involved 
in blood pressure regulation, because gene deletion of CGRP results in hypertension 
(Gangula et al , 2000). Thus, loss of CGRP-induced responses in blood vessels, as 
for example in diabetes mellitus, may result in increased risks of developing 
atherosclerosis and hypertension. 
Early studies have shown the stimulation of the cGMP/PKG pathway causes 
pro-apoptotic effects in several types of mammalian cells, including vascular smooth 
muscle cells (Pollman et al., 1996)，pancreatic beta-cells (Loweth et al., 1997) and 
colon cancer cells (Deguchi et al., 2004). However, data from our laboratory have 
shown that lower-level stimulation (and even basal activity in some cases) of the 
cGMP/PKG pathway has anti-apoptotic effects in many other cell types, including 
transformed neural cells, such as PC 12 cells (Fiscus et al, 2001), NIE-115 and 
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NG108-15 cells (Fiscus, 2002; Fiscus et al.，2002)，as well as immortalized uterine 
epithelial cells (Chan and Fiscus, 2003) and ovarian cancer cells (Fraser et al., 2006). 
Therefore, cGMP/PKG may play a dual role in the regulation of apoptosis in 
VSMCs. 
It has long been thought that the stimulation of the cGMP/PKG pathway causes 
anti-proliferative effects in VSMCs and that this response is involved in the 
NO-induced inhibition of the atherogenesis (Lincoln et al., 2001). However, recent 
data from transgenic mice, PKG-knockout and PKG-overepressing mice, have 
suggested that PKG promotes, rather than inhibits, the proliferation of VSMCs (Feil 
et al., 2005). Thus, at present the role of PKG in regulating cell proliferation rates in 
VSMCs appears contradictory. It is hoped that the data provided in this thesis will 
provide new insight concerning the role of PKG in the regulation of VSMC 
proliferation. 
Almost all of the previous reports had used VSMCs grown in culture for many 
passages, which likely resulted in phenotypic modulation (i.e. change in the cell's 
phenotype from normal "contractile" (smooth muscle) type to the abnormal 
"synthetic" (fibroblast-like) type as a result of the culturing conditions). Thus, 
previous data about the role of cGMP/PKG in the regulation of apoptosis and 
proliferation may not be representative of this pathway's role in normal VSMCs. 
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In the present study, all experiments were conducted using VSMCs in early 
passages, before the cells modulate into the synthetic, non-smooth muscle phenotype. 
The present study determines whether hyperglycemia alters cAMP responses to 
CGRP and whether the cGMP/PKG pathway plays a role in regulating apoptosis and 
proliferation in phenotypically-normal VSMCs. Because recent data from our 
laboratory had shown that rat bone marrow stromal stem cells expresses high levels 
of both the PKG-Ia and PKG-ip isoforms, very similar to VSMCs, further 
experiments were included to determined whether PKG regulates apoptosis and 
proliferation in the bone marrow stromal stem cells. 
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Chapter 2. Methods 
2.1 Measurement of cAMP and cGMP in VSMCs 
2.1.1 Cell culture 
VSMCs were isolated from Sprague-Dawley rats (250 g) as follows. The rats 
were killed by carbon dioxide and the aortas were taken out, washed in cold PBS and 
placed in a petri dish with ice-cold DMEM (Gibco) containing 0.25 |j,g/ml fungizone 
(Gibco), 400 U/ml penicillin and 400 |j,g/ml streptomycin. The adhering fat and 
adventitial layer were trimmed off. The aortas were cut open and the endothelium 
was removed by rubbing on the intima layer with sterile microforceps. Then the 
aortas were minced and incubated in 5 ml DMEM containing 3 mg/ml collagenase A 
(Roche) and 1 mg/ml hyaluronidase (Sigma) at 37°C in a humidified, 5% CO2 
incubator for 3 hours. The cells were collected by centrifugation for 3 min at 800 g, 
resuspended in DMEM containing 15% FBS, 200 U/ml penicillin and 200 |ag/ml 
streptomycin) and grown in 6-well plates. Cells were passaged every four to five 
days by harvesting with 0.5% trypsin-EDTA (Gibco). VSMCs in passage 2 to 6 were 
used in the experiments. 
The animals were provided by the Laboratory Animal Services Centre of the 
Chinese University of Hong Kong. The experimental procedures were approved by 
the Animal Experimentation Ethics Committee of the Chinese University of Hong 
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Kong and followed the "Principles of laboratory animal care" (NIH publication no. 
85-23, revised 1985) 
2.1.2 Measurements of cAMP and cGMP levels by enzyme-linked-immunoassay 
(EIA) 
Rat VSMCs in confluence in 6 wells plates were pre-incubated for 6 hours with 
10 mM, 25 mM and 44 mM glucose (BDH Analytical Supplies) in DMEM 
containing 15% FBS, 100 U/ml penicillin and 100 U/ml streptomycin. Then the cells 
were incubated with 100 nM and 1 i^M CGRP, rat type-I form (Phoenix 
Pharmaceuticals Inc, CA, USA) for 3 minutes. After incubation, the media were 
rapidly removed and 0.5 ml 0.1 N ice-cold HCl was added to each well. The cells 
were scrapped off the bottom of the culture trays and the suspensions were 
centrifuged at 10,000 rpm at 4°C for 10 minutes. The supematants were used 
immediately for cAMP/cGMP determination using the direct cAMP/cGMP 
colorimetric kit (Assay Designs Inc) as described in the manufacturer's protocol 
while the pellets were used for protein measurements by Bradford (Bio-Rad). 
Non-acetylated version and acetylated version were used in the cAMP and cGMP 
determinations, respectively. 
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2.1.3 Statistical analysis 
All experiments were repeated at least three times. Results were expressed as 
the mean 士 SEM of value from at least four experiments. Statistical analysis was 
carried out by ANOVA (PRISM software, version 3.0; GraphPad, San Diego, CA, 
USA). Differences between experimental groups were determined by the Dunett's 
test. Statistical significance was inferred at P<0.05. 
2.2 Measurement of apoptosis in VSMCs and bone marrow-derived stem cells 
2.2.1 Cell culture 
VSMCs were isolated from C57BL/6J mice as follows. Male C57BL/6J mice 
aged 8-10 weeks were killed by carbon dioxide and the aortas were taken out, 
washed in cold PBS and placed in a petri dish with ice-cold DMEM (Gibco) 
containing 0.25 |^g/ml fungizone (Gibco), 400 U/ml penicillin and 400 |ig/ml 
streptomycin. The adhering fat and adventitial layer were trimmed off. The aortas 
were minced and incubated in 5 ml isolation medium containing 3 mg/ml 
collagenase A (Roche) and 1 mg/ml hyaluronidase (Sigma) at 37�C for 4 hours. The 
cells were collected by centrifugation for 3 min at 800 g, resuspended in DMEM 
containing 15% FBS, 200 U/ml penicillin and 200 |Lig/ml streptomycin and grown in 
24-well plates. All experiments were conducted using smooth muscle cells in passage 
6 
0 cultured for 4 or 5 days. 
The animals were provided by the Laboratory Animal Services Centre of the 
Chinese University of Hong Kong. The experimental procedures were approved by 
the Animal Experimentation Ethics Committee of the Chinese University of Hong 
Kong and followed the “Principles of laboratory animal care" (NIH publication no. 
85-23，revised 1985) 
2.2.2 Hoechst 33258 staining 
Apoptosis in VSMCs were determined by Hoechst staining. After treatments, 
the VSMCs were centrifuged and the pellets were resuspended with 12.5 ng/mL 
Hoechst 33258 (Sigma) in 10% phosphate-buffered formalin overnight at 4°C. Cells 
were then examined under fluorescence microscope. 
2.2.3 Cell Death Detection ELISA Plus 
The Cell Death Detection ELISA^^^^ assay from Roche Diagnostics (Roche, 
Germany, #1774425) based on quantitative 
sandwich-enzyme-immunoassay-principle using mouse monoclonal antibodies 
directed against DNA and histories were used to quantify the apoptotic DNA 
concentration in current study. Cells were trysinized, centrifuged and the cell pellets 
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incubated in 200 i^L lysis buffer (provided by the kits) for 30 minutes at room 
temperature to allow the small apoptotic DNA fragments to be released from the 
apoptotic cells. The lysate was then centrifuged at 200 x g for 20 minutes. 20 |J.L of 
supernatant from lysate was collected without disturbing the tissue pellet and 
transferred carefully into the streptavidin coated microplate for analysis. Another 80 
|LIL of immunoreagent (a mixture of anti-histone-biotin, anti-DNA-POD and 
incubation buffer in 1:1:8 ratio) was added and the mixture was incubated under 
gently shaking at room temperature for 2 hours. After incubation, the solution was 
removed thoroughly by tapping and rinsing in 3 changes of 200 jiL incubation buffer 
for 5 minutes each. ABTS solution (provided from kit) was added as 100 [iL in each 
well for sufficient color development. The result was immediately measured by 
spectrometer with 405 nm wavelength and used ABTS + incubation buffer only as a 
blank (reference wavelength approx. 490 nm). 
2.2.4 Protein extraction and Western blot analysis of PKG expression 
Cells from different passages were trypsinzed and collected at 800 g. The cell 
pellets were resuspended and lysed for 20 min on ice in 50 )j,1 R I P A with Ix protease 
inhibitor cocktail (Roche #11836153001), 3 mM DTT (Sigma) and 150 fiM 
Microcystine-LR (Sigma). Similarly, freshly isolated aorta were homogenized in 50 
8 
M.1 RIPA by using a grinder and lysed on ice for 20 min. Then the samples were 
centrifuged at maximum speed at 4° C and the supematants used for Western blot. 
The amount of total cellular protein was measured by Bradford. The proteins were 
resolved by electrophoresis in 8% SDS-polyacrylamide gels and transferred to PVDR 
The blots were blocked in 5% nonfat milk and probed with anti-PKG (Calbiochem, 
#539729). 
2.2.5 Statistical Analysis 
All experiments were repeated at least three times. Results were expressed as 
the mean 士 SEM of value from three or four experiments. Statistical analysis was 
carried out by ANOVA (PRISM software, version 3.0; GraphPad, San Diego, CA, 
USA). Differences between experimental groups were determined by the Dunett's 
test. Statistical significance was inferred at P<0.05. 
2.3 Measurement of cell proliferation in VSMCs and bone-marrow-derived stem 
cells 
2.3.1 Cell culture 
VSMCs were isolated from C57BL/6J mice as follows. C57BL/6J mice aged 
8-10 weeks were killed by carbon dioxide and the aortas were taken out, washed in 
9 
cold PBS and placed in a petri dish with ice-cold DMEM (Gibco) containing 0.25 
|ag/ml fungizone (Gibco), 400 U/ml penicillin and 400 |ag/ml streptomycin. The 
adhering fat and adventitial layer were trimmed off. The aortas were minced and 
incubated in 5 ml isolation medium containing 3 mg/ml collagenase A (Roche) and 1 
mg/ml hyaluronidase (Sigma) at 37°C for 4 hours. The cells were collected by 
centrifugation for 3 min at 800 g, resuspended in DMEM containing 15% FBS, 200 
U/ml penicillin and 200 ^ig/ml streptomycin and grown in 24-well plates. All 
experiments were conducted using smooth muscle cells in passage 0 cultured for 4 or 
5 days. 
Adult male C57BL/6J mouse (aged 8-10 weeks) were used in all experiments. 
The animals were provided by the Laboratory Animal Services Centre of the Chinese 
University of Hong Kong. The experimental procedures were approved by the 
Animal Experimentation Ethics Committee of the Chinese University of Hong Kong 
and followed the "Principles of laboratory animal care" (NIH publication no. 85-23, 
revised 1985) 
2.3.2 Cell count 
Cells were seeded in 24-well plates in DMEM with 15% FBS and then 
incubated at 37 °C in 5% CO2 for 24 h. Then DT-2 (Biolog) or DT-3 (Calbiochem) at 
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0，125, 250 and 1000 nM were added to the medium for 3 days and were added once 
every 24 h. Cells were trysinized from the wells after experiments, using 2.5% (lOx) 
trypsin-EDTA (Gibco). Cell numbers were counted by a hemocytometer. The number 
of cells were counted before and after the PKG inhibitors were added. The increase 
in number of cells were calculated by subtracting the initial cell number from the cell 
number after treatment of the inhibitors. 
2.3.3 MTT assay 
Metabolic activities of the VSMCs are measured by the MTT assay (Roche). 
Cells were seeded in 96-well microplates (2 x 10'^  cells per well) in DMEM with 
15% FBS and then incubated at 3 7 � C in 5% CO2 for 24 h. Then DT-2 (Biolog) or 
DT-3 (Calbiochem) at 0，125, 250 and 1000 nM were added to the medium for 3 days 
and were added once every 24 h. Then 10 />tl of MTT (5 mg/ml) in PBS was added to 
each well and incubated for 4 h. 100/xl of solubilizing solution was added to each 
well and allowed to incubate overnight at 37 °C in 5% CO2 to dissolve the formed 
crystal formazan. The absorbance was measured by a microplate reader at 550 nm 
with a reference wavelength of 690 nm. 
2.3.4 BrdU-(5'Bromo-2-deoxyuridine) ELISA colorimetric assay 
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The rate of DNA synthesis of VSMCs was measured by the non-radioactive 
BrdU-(5 TBromo-2-deoxyuridine) ELISA colorimetric assay (Roche). Cells were 
seeded in 96-well microplates (5 x 10^ cells per well) in DMEM with 15% FBS and 
then incubated at 37 °C in 5% CO2 for 24 h. Then DT-2 (Biolog) or DT-3 
(Calbiochem) at 0，125, 250 and 1000 nM were added to the medium for another 24 
h. Subsequently, 10 pii BrdU was added to each well and reincubated for 4 h. The 
anti-BrdU-POD binds to the BrdU incorporated in newly synthesized, cellular DNA. 
The substrate TMB was added and the reaction product was quantified by a 
microplate reader at 370 nm with a reference wavelength of 492 nm. 
2.3.5 Statistical analysis 
All experiments were repeated at least three times. Results were expressed as the 
mean 士 SEM of value from at least four experiments. Statistical analysis was 
carried out by ANOVA (PRISM software, version 3.0; GraphPad, San Diego, CA， 
USA). Differences between experimental groups were determined by the Dunett's 
test. Statistical significance was inferred at P<0.05. 
12 
Chapter 3. Effects of hyperglycemia on CGRP-induce cAMP 
response in VSMCs 
3.1 Introduction 
Calcitonin gene-related peptide (CGRP) is a 37-amino acid neuropeptide 
expressed predominantly in the central and peripheral nervous systems 
(Wimalawansa, 1996). CGRP receptors are widely distributed in the body. CGRP 
plays multiple roles in the cardiovascular system and is reported to be the most 
potent endogenous vasodilator in humans that has been discovered to date. CGRP is 
thought to be involved in the regulation of peripheral vascular tone and regional 
organ blood flows in normal physiological conditions through 
endothelium-dependent or endothelium-independent mechanisms, depending on the 
type of blood vessel (Edvinsson et al.，1985; Shoji et al.，1987; Fiscus, 1988). CGRP, 
released from afferent nerves (c-fiber) in arterial walls, binds CGRP receptor on 
VSMCs (Kubota et al , 1985, Hirata et al. 1988). The Gs protein-coupled CGRP 
receptor causes elevation of cAMP and vasodilation (Figure 3.1). Thus, CGRP and 
its agonists or antagonists have been considered to become therapeutic agents for 
many heart diseases and hypertension. Our laboratory has shown that the 
endothelium-dependent vasorelaxations of CGRP involve nitric oxide (NO) released 
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from endothelium and NO-dependent elevations of both cAMP and cGMP levels in 
VSMCs (Fiscus et al.，1991). Moreover, CGRP has anti-proliferative effects on 
VSMCs (Li et al., 1997). The vasodilatory (Fiscus et al, 1994) and anti-proliferative 
(Wang et a l , 1999) effects of CGRP are synergistically enhanced by NO. Also, NO 
donors enhance CGRP-induced elevations of cAMP in VSMCs (Lu and Fiscus, 
1999). 
Cardiovascular disease is the leading cause of death among patients with 
diabetes, accounting for over 60% of mortality (Desai et al., 2005). Diabetes is 
recognized as an important risk factor for the development of atherosclerosis and 
vascular complications, like hypertension, macro- and micro- vascular damage. For 
example, development of coronary atherosclerosis is associated with heart attack, 
while atherosclerotic lesions in cerebral arteries are associated with stroke. 
CGRP is thought to inhibit the development of atherosclerosis by inhibiting the 
proliferation of VSMCs (Li et al , 1997). Also, CGRP is likely involved in blood 
pressure regulation, because gene deletion of CGRP results in hypertension (Gangula 
et al., 2000). Thus, loss of CGRP-induced responses in blood vessels, as for example 
in diabetes mellitus，may result in increased risks of developing atherosclerosis and 
hypertension (Figure 3.2). Data from our laboratory have shown that 
endothelium-dependent relaxations in aortic rings caused by CGRP are severely 
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impaired in diabetic rats (Fiscus et al.，2001). CGRP-induced hypotensive responses 
in vivo are also severely impaired in small resistance-sized arteries of diabetic rats 
(Fiscus et al., 2001). Figures 3.1 and 3.2 show cellular models that illustrate the 
potential role of CGRP in regulating arterial blood pressure and development of 
atherosclerosis, and how these responses may become impaired during diabetes 
mellitus. The effect of diabetes on CGRP-induced cAMP responses has not been 
demonstrated. Therefore, the aim of the present study is to examine the effect of 
hyperglycemia on CGRP-induced vascular cAMP responses in cultured VSMCs. 
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Figure 3.1 CGRP, released from afferent nerves (c-fiber) in arterial walls, binds 
CGRP receptor on VSMCs. The CGRP-receptor, coupled to Gs protein, activates 
adenylate cyclase and causes elevation of cAMP. Then cAMP binds to the regulatory 
subunits of PKA and causes the catalytic subunits to dissociate, thereby mediating 
vasodilation and anti-proliferative effects in VSMCs. 
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3.2 Results 
Rat VSMCs from passage 6 were preincubated for 6 hours with 10，25 and 44 
mM glucose (Figure 3.3). The cAMP response to CGRP was significantly diminished 
both at 25 mM and 44 mM. Note that 25 mM glucose, the normal culturing glucose 
concentration, can already cause such a diminished effect. Because the VSMCs in 
this first experiments may have become phenotypically modulated because of the 
passaging, further experiments were performed using VSMCs in earlier passages. 
VSMCs from passage 2 to 3, which were phenotypically normal, shows a similar 
pattern, However, in these cells the CGRP-induced increases in cAMP levels are 
considerably smaller, more like in freshly isolated smooth muscle cells (Fiscus et al , 
1991) and the suppressing effect of the hyperglycemia was much larger (Figure 3.4). 
The corresponding cGMP levels in those early passages of VSMCs after exposure to 
the different concentrations of glucose were also measured. At the higher glucose 
concentration, cGMP levels appeared to be somewhat elevated above control levels, 
but this was not statistically significant at the 5% levels (Figure 3.5). 
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Figure 3.3 CGRP-induced cAMP responses in VSMCs in passage 6. lOmM glucose 
was used as the control group. * indicates p<0.05, *** indicates p<0.001. After 
6-hour preincubation with 44 mM glucose the cAMP response to CGRP was 
significantly diminished. Even at 25 mM glucose, which is, the common 
concentration used in cell cultures, also significantly cause a diminished response. 
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Figure 3.4 Hyperglycemia-induced suppression of the cAMP response to CGRP was 
much larger in earlier passages (p2-3) of VSMCs (i.e. phenotypically normal). * 
indicates p<0.05, *** indicates p<0.001. Preincubation with 44 mM and 25 mM 
glucose both caused a dimished cAMP response, but the hyperglycemia-induced 
suppression of the CGRP-induced cAMP response was much larger in earlier 
passages of VSMCs, which were phenotypically normal. The data represent the mean 
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Figure 3.5 shows the cGMP levels in cells preincubated for 6 h with different 
concentrations of glucose in early passages of VSMCs. The data represent the mean 
士 SEM of four observations per treatment group. 
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3.3 Discussion 
Vascular dysfunction is a well-established complication of diabetes mellitus. It 
is suggested that failure in the adaptive coronary flow response to cardiac 
hyperactivity in diabetic subjects may, in part, be responsible for the higher incidence 
of ischemic heart disease in the diabetic population (Durante et al., 1989). In 
streptozotocin(STZ)-induced diabetic animals, the severity and duration of diabetes 
and insulin treatment are important factors affecting both endothelium-dependent and 
-independent vascular responses to various vasoactive agents (One & Aloamaka, 
1993; Taylor et al., 1994; Savage et al., 1995; Pieper, 1997; Rodriguez-Manas et al., 
1998; Van-Buren et al., 1998; Kobayashi & Kamata, 1999). It has also been shown 
that long-term streptozotocin-induced diabetic rats have a selective depression of 
CGRP-induced relaxation in the intramural coronary arteries (Sheykhzade et al.， 
2000). Moreover, the insulin-mediated vascular and blood pressure responses are 
suppressed in CGRP-deficient normal and diabetic rats (Salem et al., 2002). Data 
from our laboratory have shown that endothelium-dependent relaxations in aortic 
rings caused by CGRP are severely impaired in diabetic rats (Fiscus et al., 2001). 
The endothelium-dependent vasorelaxations of CGRP involve NO released from 
endothelium and NO-dependent elevations of both cAMP and cGMP levels in 
VSMCs (Fiscus et al., 1991). Data from our lab have shown that CGRP-induced 
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hypotensive responses in vivo are also severely impaired in small resistance-sized 
arteries of diabetic rats (Fiscus et al.，2001). 
The present study further investigated the effect of hyperglycemia on 
CGRP-induced vascular response in cultured VSMCs. For a period as short as a 
6-hour preincubation with 44 mM glucose, the cAMP response to CGRP was 
significantly diminished. Even at 25 mM glucose, which is the common 
concentration used in cell cultures, also significantly caused a diminished response 
(Figure 3.3). Interestingly, when earlier passages of VSMCs (phenotypically normal) 
are used, the hyperglycemia-induced suppression of the CGRP-induced cAMP 
response is much larger (Figure 3.4). 
The increased cAMP response to CGRP in later passages of VSMCs may be due 
to several reasons. It has been established that phenotypic modulation occurs during 
passaging of rat VSMCs. Rat VSMCs at early passages have a more contractile 
phenotype, with a spindle-shaped morphology and higher expression levels of 
smooth muscle specific myosin heavy chain, calponin and a-actin. In contrast, rat 
VSMCs at later passages like passage 5 or 6, have a more synthetic phenotype and 
fibroblastic morphology. It has been suggested that regulation of PKG gene 
expression or nitric oxide/cGMP/PKG pathway controls phenotype (Lincoln et al , 
2001). Moreover, restoration of PKG expression to the synthetic phenotype VSMCs 
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results in the cells acquiring a more contractile phenotype (Brothy et al., 2001). 
Since vascular disorders are related to the accumulation of synthetic, 
fibroproliferative VSMCs in the vessel wall, using cultured rat VSMCs in later 
passages would be an appropriate model for studying the underlying mechanisms. 
Nonetheless, it has been shown that phosphodiesterase 3 (PDE3) activity was 
reduced in synthetic VSMCs (Dunkerley et al., 2002)，which may account for the 
accumulation of cAMR Moreover, it has been shown that in VSMCs of diabetic rats, 
eNOS expression was increased (Pandolfi et al., 2003). The increased eNOS 
expression may provide NO for stimulation of sGC/cGMP pathway, which then 
blocks the PDE3 and causes accumulation of cAMR Data from the present study also 
shows that the cGMP level may be increased (although this was not statistically 
significant) when cells were exposed to hyperglycemia (Figure 3.5). 
It is still not clear how hyperglycemia affects CGRP-induced vascular responses 
in VSMCs. However, elevation of blood glucose levels during diabetes mellitus is 
known to cause glycosylation and/or conformational changes of proteins (e.g. 
collagen and receptors) in the wall of arteries, leading to damage and loss of vascular 
responses (Fiscus and Ming, 2000). Even normal levels of blood glucose are thought 
to cause similar glycosylation of proteins, but at a slower rate. Genetic studies have 
indicated that potential sites for glycosylation in the CGRP receptor are located 
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extracellularly in the first transmembrane segment (Njuki et al., 1993). Over time, 
this can lead to changes in receptor function and subsequent impairment of vascular 
responses. Therefore, taken together with previous data from our lab showing that 
diabetes caused severe impairment of CGRP-induced hypotensive responses in vivo 
(Fiscus et al., 2001), the present study has demonstrated that the hyperglycemia 
diminishes CGRP-induced cAMP responses. Further studies are needed to determine 
the molecular mechanism of the diminished vascular responses to CGRP in diabetes 
mellitus. 
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Chapter 4. Role of cGMP and protein kinase G (PKG) in 
regulation of apoptosis in VSMCs 
4.1 Introduction 
Early studies have shown the stimulation of the cGMP/PKG pathway causes 
pro-apoptotic effects in several types of mammalian cells, including vascular smooth 
muscle cells (Pollman et al., 1996), pancreatic beta-cells (Loweth et al , 1997) and 
colon cancer cells (Deguchi et al., 2004). However, data from our laboratory have 
shown that lower-level stimulation (and even basal activity in some cases) of the 
cGMP/PKG pathway has anti-apoptotic effects in many other cell types, including 
transformed neural cells, such as PC 12 cells (Fiscus et al, 2001), NIE-115 and 
NG108-15 cells (Fiscus, 2002; Fiscus et al., 2002)，as well as immortalized uterine 
epithelial cells (Chan and Fiscus, 2003) and ovarian cancer cells (Fraser et al , 2005). 
Therefore, the present study hypothesized that cGMP/PKG may play a dual role in 
the regulation of apoptosis in VSMCs and that only one part (pro-apoptotic effect) of 
the regulatory mechanism of cGMP/PKG has been reported. Adding support to this 
idea, more recent studies from our laboratory have shown that the anti-apoptotic role 
of cGMP/PKG is not limited to just transformed or partially transformed (i.e. 
immortalized) cells, but also plays an important role in limiting spontaneous onset of 
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apoptosis in certain normal (non-transformated) cells. For example, our laboratory 
has recently shown that the basal cGMP/PKG activity is essential to prevent 
spontaneous onset of apoptosis in isolated pancreatic islets (unpublished data from 
our lab). Figure 4.1 summarizes the different types of mammalian cells that appear to 
require low-level or basal-level activation of the cGMP/PKG pathway for prevention 
of spontaneous apoptosis. 
Of interest, pancreatic beta-cells showed both pro-apoptotic effects (Loweth et 
al., 1997) and anti-apoptotic effects (unpublished data from our laboratory) mediated 
by the cGMP/PKG pathway. The difference in response appears to depend on the 
level of stimulation of this pathway. For instance, hyperstimulation of cGMP/PKG 
causes pro-apoptotic effects, while low-level stimulation (such as basal-level 
stimulation) of cGMP/PKG causes cytoprotective/anti-apoptotic effects. Because in 
earlier studies, VSMCs have been shown to have a pro-apoptotic response to 
cGMP/PKG stimulation (Pollman et al., 1996)，which was likely a high-level 
stimulation, our hypothesis is that cGMP/PKG may play a dual role (i.e. 
pro-apoptotic effects at high-level stimulation and anti-apoptotic effects at low-level 
stimulation) in the regulation of apoptosis in VSMCs. 
Furthermore, previous data from our laboratory have shown that preincubation 
with the natriuretic peptide ANP can protect NG108-15 cells against the 
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toxic/pro-apoptotic effects of excess NO (Cheng Chew et al., 2003). Thus, the 
objective of the present study was to use the Hoechst 33258 staining and the Cell 
Death Detection ELISA method to quantify the levels of apoptosis in VSMCs 
exposed to different concentrations of NO, using the NO donor 
S-nitroso-N-acetylpenicillamine (SNAP), and to determine if preincubation with 
ANP (a pure cGMP-elevating agent) can protect the VSMCs against the toxic effects 
of the excess NO. In the present study, we also used the sGC inhibitor, 
1 H-[ 1,2,4]oxadiazolo[4,3,-a]quinoxalin-1 -one (ODQ), and various PKG inhibitors 
(KT-5823, DT-2 and DT-3), to determine if basal sGC/cGMP activity and basal 
PKG activity are involved in regulating apoptosis of VSMCs, respectively. 
Phenotypically normal VSMCs (in passage 0) were used throughout the present 
study. 
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cGMP/PKG Signaling Pathway Protects Against the Spontaneous 
Onset of Apoptotic Cell Death in Mammalian Cells 
Transformed Ovarian Immortalized uterine 
neural cells cancer cells epithelial cells 
Transformed or partially ^ ^ 
transformed cells 
Anti-apoptotic effects of basal cGMP levels 
and 
Normal cells in basal PKG activity 
primary culture ^ ^ 
Pancreatic Vascular smooth Bone-marrow-
Islets muscle cells ？ derived stem cells ？ 
Figure 4.1 Summary of anti-apoptotic effects of basal or low-level activation of the 
cGMP/PKG pathway in mammalian cells 
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4.2 Results 
Using Hoechst 33258 staining to determine the presence of apoptosis in the 
VSMCs, the NO donor SNAP appeared to have a dual effect on VSMCs, 
anti-apoptotic effects when SNAP was added at low concentrations (10 and 50 \xM), 
but pro-apoptotic/cytotoxic effects when SNAP was added at higher concentrations 
(Figure 4.2). Furthermore, the level of apoptosis as quantified by Cell Death 
Detection ELISA showed a similar pattern in VSMCs (Figure 4.3). However, the 
observed decrease in apoptosis with low-level NO was not statistically significant at 
the 5% level. SNAP clearly had pro-apoptotic/cytotoxic effects when added at the 
highest concentration, i.e. 500 |aM (***P<0.001). The cGMP levels in the VSMCs 
after incubation with SNAP for 4 min were also measured (Figure 4.4). 
The levels of apoptosis were measured by Cell Death Detection ELISA in 
VSMCs treated with the soluble guanylyl cyclase (sGC) inhibitor, 1H-[1，2，4] 
-oxadiazolo [4,3-a] quinoxalin-l-one (ODQ) (Figure 4.5). ODQ, at concentrations 
that would be considered appropriate for selective inhbition of sGC (i.e. 3 - 30 jaM 
ODQ) had no effect on apoptosis in the VSMCs. Although a significant increase in 
apoptosis was observed at the 100 |j.M concentration, it is likely that this apoptotic 
response was caused by a non-specific/toxic effect of ODQ, instead of the specific 
inhibitory effect on sGC. Interestingly, ODQ had no effect on cGMP levels in 
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VSMCs (Figure 4.6), which is in sharp contrast to the cGMP-lowering effects of 
ODQ observed in most other cells (Fiscus, 2002; Chan and Fiscus, 2003). 
Pretreatment with 8-Br-cGMP before the induction of apoptosis with high-level 
SNAP (1 mM), i.e. high-level NO-induced toxicity in VSMCs, showed a trend 
toward inhibition of the SNAP-induced apoptosis. (Figure 4.7). 8-Br-cGMP is known 
to be metabolized by many phosphodiesterases and therefore may have had a 
transient effect within the VSMCs. Thus, it is likely that 8-Br-cGMP was not able to 
last during the 24 h exposure, and thus was not able to consistently affect the 
SNAP-induced apoptosis. On the other hand, preincubated with ANP causes 
complete protection against SNAP-induced apoptosis, even when ANP is used at 
concentration as low as 10 nM (*P<0.05) (Figure 4.8). Figure 4.9 shows that the 
VSMCs of the present study do indeed respond to ANP with increases in cGMP 
levels. ANP is known to cause a very prolonged increase of cGMP levels (Zhou and 
Fiscus, 1988 and Fiscus, Tu and Chung Chew, 2001)，which likely lasts long enough 
for protection against apoptosis during the 24 h exposure to SNAP. 
To further investigate the apoptotic/anti-apoptotic role of the cGMP/PKG 
pathway, the effect on apoptosis of various PKG inhibitors were studied in the 
VSMCs. Two inhibitors were used; KT5823, a commonly-used selective PKG 
inhibitor, and DT-2, a newly-developed highly-specific PKG inhibitor. Figure 4.10 
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shows the unique characteristics of DT-2 that make it so specific for PKG and that 
allow it to be transported into mammalian cells. Figure 4.11 shows the results of the 
experiments testing the effects on apoptosis of the PKG inhibitors. Apoptosis was 
measured by Cell Death Detection ELISA. The PKG inhibitors had no effect on 
apoptotic levels in the presence of serum. Likely, another signaling pathway, such as 
the Akt/protein kinase B cytoprotective pathway, was activated by serum factors, 
thus providing an anti-apoptotic signal that was independent of PKG. However, in the 
absence of serum (-S) for 72 h, DT-2 (250 nM) and DT-3 (250 nM) significantly 
(***p<0.001) enhanced the pro-apoptotic effects of serum deprivation by 2-fold and 
3-fold, respectively. Thus, basal PKG activity provided an anti-apoptotic signal that 
limited the apoptosis during serum deprivation. 
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Figure 4.2 shows fluorescent images of Hoechst 33258 staining of VSMCs treated 
with the NO donor, S-nitroso-N-acetylpenicillamine (SNAP) for 72 h without serum. 
NO appears to have anti-apoptotic effects when added at low concentrations (10 and 
50 jiM), but pro-apoptotic/cytotoxic effects when added at higher concentrations. 
Although preliminary, the data suggest that NO may have a dual effect on VSMCs, 
preventing apoptosis at lower concentrations and promoting apoptosis at higher 
concentration. The image set was representitve of three experiments. 
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Figure 4.3 shows the level of apoptosis as quantified by Cell Death Detection ELISA 
in VSMCs treated with the SNAP for 72 h in the absence of serum, consistent with 
the data from Hoechst staining technique. Although the observed decrease in 
apoptosis was not statistically significant at the 5% level, NO still appears to have 
anti-apoptotic effects when added at low concentrations (10 and 50 \xM). SNAP 
clearly had pro-apoptotic/cytotoxic effects when added at the highest concentration, 
i.e. 500 iiM (***P<0.001). The data represent the mean 士 SEM of four observations 
per treatment group. 
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Figure 4.4 shows the cGMP level in VSMCs after incubation with SNAP for 4 min. 
The data represent the mean 士 SEM of four observations per treatment group. 
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Figure 4.5 shows the levels of apoptosis measured by Cell Death Detection ELISA in 
VSMCs treated with the soluble guanylyl cyclase (sGC) inhibitor, 1H-[1，2，4] 
-oxadiazolo [4,3-a] quinoxalin-l-one (ODQ), for 72 h in the absence of serum. ODQ, 
at concentrations that should effectively inhibit sGC (i.e. 10 and 40 ^iM), had no 
effect on apoptosis of VSMCs. Although a significant increase in apoptosis was 
observed at the 100 i^M concentration, it is likely that this apoptotic response was 
caused by a non-specific/toxic effect of ODQ, instead of the specific inhibitory effect 
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Figure 4.6 shows the cGMP levels measured by in VSMCs treated with the soluble 
guanylyl cyclase (sGC) inhibitor, ODQ, for 72 h in the absence of serum. ODQ, at 
concentrations that should effectively inhibit sGC (i.e. 10 and 40 |iM), did not lower 
the levels of cGMP in VSMCs. The data represent the mean 士 SEM of four 
observations per treatment group. 
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Figure 4.7 Pretreatment with 8-Br-cGMP for 24 h before the SNAP (1 mM)-induced 
apoptosis in the absence of serum appears to have anti-apoptotic effects in VSMCs. 
Although not statistically significant, the data show a trend toward inhibition of 
SNAP-induced apoptosis. The data represent the mean 士 SEM of four observations 
per treatment group. 
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Figure 4.8 Anti-apoptotic effects ofANP (10，100 and 1000 nM) pretreatment against 
SNAP (1 mM)-induced apoptosis in the absence of serum in VSMCs. When 
preincubated with ANP at concentration as low as 10 nM (*P<0.05), the 
SNAP-induced apoptosis was completely inhibited. The data represent the mean 士 
SEM of four observations per treatment group. 
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Figure 4.9 cGMP levels in VSMCs after incubation with ANP for 4 min. The data 
represent the mean 士 SEM of four observations per treatment group. 
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DT-2 is a fused peptide: 
YGRKKRRQRRRPPI-ILRKKKKKH 
Membrane translocation PKG-inhibitory peptide 
sequence from HIV-tat (developed using combinatory 
protein (a.a 47-59) chemistry & screening >1,000 
potential inhibitors) 
(Dostmann et al., 2000，2002) 
Figure 4.10 The amino acid sequence of DT-2, the highly specific inhibitor of PKG 
developed by Dostmann et al. DT-2 is a fused peptide composed of a membrane 
translocation sequence from HIV-tat protein and a PKG-inhibitory peptide that binds 
with high affinity to the protein substrate binding site, allowing DT-2 to be 
cell-permeable as well as a potent and specific inhibitor of endogenous PKG. 
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Figure 4.11 The levels of apoptosis as quantified by Cell Death Detection ELISA in 
VSMCs treated with various PKG inhibitors for 72 h in the absence of serum. The 
PKG inhibitors had no effect on apoptotic levels in the presence of serum (+S), 
suggesting that basal PKG activity was not essential for preventing apoptosis in 
VSMCs when cultured with serum. However, in the absence of serum (-S) for 72 h, 
DT-2 (250 nM) and DT-3 (250 nM) significantly (***p<0.001) enhanced the 
pro-apoptotic effects of serum deprivation by 2-fold and 3-fold, respectively. 
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KT-5823 had no effect, likely because of its weaker and less specific effects on PKG 




Nitric oxide is thought to participate in the physiological regulation of vascular 
tone as well as the pathological cell death that occurs in certain diseases, like 
diabetes mellitus (Isner et al, 1995, atherosclerosis (Han et al., 1995) and restenosis 
(Shaw et al., 2005). Apoptotic cell death plays a central role during vascular 
remodeling and lesion formation in animal models (Bochaton-Piallat et al., 1995; 
Bauriedel et al., 1997). However, the role of NO in the onset of apoptosis of VSMCs 
during the pathogenesis of these diseases has not been clearly defined. In cultured 
VSMCs, stimulation of the cGMP/PKG pathway by NO has been proposed to cause 
pro-apoptotic effects (Pollman et al., 1996; Fukuo et al., 1996; Chiche et al., 1998). 
However, NO has also been proposed to be protective against apoptosis in VSMCs 
(Dimmeler et al., 1997a; Dimmeler et al , 1997b)，although the role of the 
cGMP/PKG pathway in this anti-apoptotic effect was not determined in these 
reports. 
Data from our laboratory have shown that lower-level stimulation (and even 
basal activity, in some cases) of the cGMP/PKG pathway has anti-apoptotic effects in 
many cell types, including transformed neural cells, such as PC 12 cells (Fiscus et al, 
2001), NIE-115 and NG108-15 cells (Fiscus, 2002; Fiscus et al , 2002)，immortalized 
uterine epithelial cells (Chan and Fiscus, 2003) and ovarian cancer cells (Fraser et al., 
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2006). Moreover, more recent data in pancreatic islets from our laboratory have 
shown that NO has a dual role, i.e. pro-apoptotic effects at high-level stimulation and 
anti-apoptotic effects at low-level stimulation (unpublished data). NO may play a 
similar dual role in the regulation of apoptosis in VSMCs. 
In the present study, the NO donor SNAP was used in a wide concentration 
range to determine if NO has both pro-apoptotic and anti-apoptotic effects in VSMCs. 
Indeed, NO at low concentrations, provided by SNAP (10 and 50 appears to 
have an anti-apoptotic effect in VSMCs (although the responses were not consistent 
enough to be statistically significant at the 5% level). SNAP at 10 and 50 i^M 
reduced the levels of apoptosis to 40% and 30%, respectively, of the control levels. 
SNAP at these lower concentrations likely released NO at a rate that would cause 
accumulation of physiological (or slightly higher than physiological) concentrations 
of NO (i.e. 1 - 20 nM). NO at these lower concentrations is capable of stimulating 
sGC and causing modest increases in the cGMP levels within VSMCs, which may 
protect these cells against spontaneous apoptosis. At higher levels of SNAP, excess 
NO would be produced, causing accumulation of NO that could be toxic to the 
smooth muscle cells. In the present study, SNAP at 500 caused a 4-fold 
increase in the levels of apoptosis. The pro-apoptotic effect observed here was 
consistent with the earlier studies, showing that NO at higher concentrations causes 
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onset of apoptosis in VSMCs, which appeared to be mediated by high-level 
stimulation (hyperstimulation) to the cGMP/PKG pathway (Pollman et al., 1996). 
Thus, low-level stimulation of the cGMP/PKG pathway may have anti-apoptotic 
effects, whereas high-level stimulation of the cGMP/PKG pathway may have 
pro-apoptotic effects in the VSMCs. These pro-apoptotic effects of high-level SNAP 
and high-level stimulation of the cGMP/PKG pathway in VSMCs may be related to 
certain pathological conditions, such as atherosclerosis and inflammation, which are 
known to involve an exaggerated production of NO (Fiscus, 2002). 
Previous data from our laboratory had shown that ODQ, a sGC inhibitor, 
triggers onset of apoptotic DNA fragmentation in immortalized uterine epithelial 
cells (Chan and Fiscus, 2003) and NG108-15 cells (Fiscus, 2002, Fiscus et al., 2002). 
Our laboratory has also found similar induction of apoptosis caused by ODQ in 
primary cultures of pancreatic islets (unpublished data). However, in the present 
study, ODQ did not cause apoptosis in VSMCs even at concentration as high as 80 
\xM, unlike observed previously in the various cells mentioned above. ODQ was also 
unable to cause a decrease in cGMP levels in VSMCs (Figure 4.6). One possible 
explanation for the lack of effect of ODQ is that basal levels of cGMP are not 
dependent on sGC activity in VSMCs. Instead, the particulate form of guanylyl 
cyclase (pGC) may be more important for providing the basal levels of cGMP in 
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these cells. 
Previously, data from our laboratory had shown that two natriuretic peptides, 
ANP and the closely related B-type (brain) natriuretic peptide (BNP), inhibit the 
onset of apoptosis and prolong the survival of serum-deprived PC 12 cells (Fiscus et 
al. 2001b; Fiscus, 2002). This anti-apoptotic/neuroprotective effect appeared to 
involve the cGMP signaling pathway, because both ANP and BNP caused prolonged 
elevations of cGMP (but not cAMP) levels in the PC 12 cells and the exposure of the 
serum-deprived PC 12 cells to a cell-permeable analog of cGMP caused similar 
anti-apoptotic effects. Our laboratory also showed that ANP could protect another 
neural cell line, NG108-15 cells, against the onset of apoptosis induced by 
high-level/toxic-level SNAP (Cheng Chew et al, 2003). 
In the present study, two cGMP elevating agents, 8-Br-cGMP and ANP, were 
used for pretreatment of the VSMCs before addition of toxic levels of the NO donor 
SNAP. Because high-level SNAP likely causes very rapid toxic effects (i.e., 
oxidation and nitration) in the cells, 8-Br-cGMP and ANP would need to be added to 
the cells at least several hours before the exposure to SNAP in order to give enough 
time to activate the anti-apoptotic/protective mechanisms. SNAP, by itself, elevates 
cGMP levels in VSMCs (Figure 4.4) and simultaneously causes apoptosis, so it is 
clear that a cGMP response occurring at the same time as exposure to excess NO 
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cannot protect these cells against the induction of apoptosis. Thus, based on previous 
studies from our lab, it was predicted that a pretreatment with 8-Br-cGMP or ANP 
and prior activation of the cGMP signaling pathway in the VSMCs, before the 
exposure to SNAP would be needed to obtain the protective effect against 
SNAP-induced apoptosis. 
In the present study, pretreatment with 8-Br-cGMP for 24 h before exposure to 
the pro-apoptotic levels of SNAP (1 mM) appears to have anti-apoptotic effects in 
VSMCs. Although not statistically significant, the data show a trend toward 
inhibition of SNAP-induced apoptosis. One reason for the lack of a clear 
anti-apoptotic effect of 8-Br-cGMP is that this cGMP analog is metabolized by 
various phosphodiesterases (Zimmerman et al., 1985) and therefore may have a 
transient effect which may not be able to last during the 48 h exposure to SNAP. A 
more clear protective effect was obtained with ANP, which can elevated cGMP and 
stimulate PKG activity for a prolonged period of time. For example, pretreatment 
with ANP for 24 ha t 10, 100 and 1000 nM significantly (*p<0.05) protected VSMCs 
against SNAP (1 mM)-induced apoptosis. ANP is known to cause a very prolonged 
increase of cGMP levels (Zhou and Fiscus, 1988; Fiscus et al , 2001b). When 
preincubated with ANP at a concentration as low as 10 nM (*P<0.05), complete 
inhibition of SNAP-induced apoptosis was observed. The inhibition of apoptosis in 
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VSMCs likely relates to the increased cGMP levels induced by the pretreatment with 
ANP. Thus, increased levels of cGMP before the excess NO stress appears to play an 
important role as an anti-apoptotic/cytoprotective mechanism. 
In contrast to the anti-apoptotic/cytoprotective effects of the cGMP/PKG 
pathway observed in the present study, previous studies by other laboratories have 
shown that stimulation of the cGMP/PKG pathway causes pro-apoptotic effects in 
VSMCs (Pollman et al., 1996; Fukuo et al., 1996; Chiche et al., 1998). In these 
previous studies, two commonly-used PKG inhibitors, KT-5823 and 
Rp-8-pCPT-cGMPS, were used to demonstrate the pro-apoptotic effect of PKG 
However, these PKG inhibitors may lack specificity. For example, KT-5823 is known 
to inhibit PKG enzymatic activity via its ability to block the ATP binding site of the 
enzyme (Hidaka et al., 1992). Because the ATP binding site is highly conserved in 
many types of protein kinases, KT5823 likely inhibits the activity of many other 
kinases (Burkhardt et al., 2000)，resulting in lack of specificity. Furthermore, 
Rp-8-pCPT-cGMPS may inhibit PKA as well as PKG (Butt et al , 1994). 
Recently, a unique, highly-specific PKG inhibitor, named DT-2, became 
commercially available, based on the development by Dostmann's group (Dostmann 
et al., 2000). In short, DT-2 is a fusion peptide, which consists of a membrane 
translocation sequence from amino acid 47 - 59 of HIV-tat protein and a 
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PKG-inhibitory peptide sequence (Figure 4.10). The PKG-inhibitory peptide 
sequence was developed using combinatory chemistry and the subsequent screening 
of over 1,000 potential peptide inhibitors (Dostmann et al.，1999; Dostmann et al.， 
2000; Honda et al., 2001; Dostmann et al., 2002). This highly charged peptide has 
been proven to be efficiently delivered into cells (Dostmann et al , 2000). Also, DT-2 
is very specific for PKG (over 1,000-fold selectivity for PKG compared to other 
protein kinases) and is actively transported across the cell membrane, thus allowing 
very low concentrations to be used, especially in experiments that use incubation 
time of more than 1 hour (Dostmann et al., 2000; Honda et al , 2001). Moreover, of 
the PKG inhibitors mentioned, only DT-2 is capable of decreasing the 
cGMP-independent activity of PKG (i.e. the activity of PKG without the presence of 
cGMP, which is typically about 10% of the activity of fully-activated PKG). In 
contrast, KT5823 and the Rp-compounds cannot inhibit the cGMP-indpendent 
activity of PKG (Taylor et al., 2004). In fact, in the case of the Rp-compound that are 
suppose to inhibit PKG activity, they can actually stimulate PKG activity above basal 
levels, because they can act as partial agonist (partial stimulants) at the 
cGMP-activating site of PKG Thus, in the present study, DT-2 and a related peptide, 
DT-3, which contains the same highly-specific PKG inhibitory sequence LRK5H 
(W45) fused to a different membrane translocation sequence {HIV-1 tat protein for 
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DT-2 or Drosophila Antennapedia for DT-3) was used to investigate the role of basal 
PKG activity in the onset of apoptosis in VSMCs. 
The present study shows that inhibition of basal PKG activity enhances the level 
of apoptosis induced by serum-deprivation. The PKG inhibitors had no effect on 
apoptotic levels in the presence of serum (+S), suggesting that basal PKG activity 
was not essential for preventing apoptosis in VSMCs when cultured with serum. 
Likely another signaling pathway (e.g. Akt/protein kinase B) was activated by serum 
factors, thus providing an anti-apoptotic signal independent of PKG. However, in the 
absence of serum (-S) for 72 h, DT-2 (250 nM) and DT-3 (250 nM) significantly 
(***p<0.001) enhanced the pro-apoptotic effects of serum deprivation by 2-fold and 
3-fold, respectively. KT-5823 had no effect, likely because of its weaker and less 
specific effects on PKG inhibition. Thus, basal PKG activity provided an 
anti-apoptotic signal that limited the apoptosis during serum deprivation. 
Taken together, the results of the present study suggest a dual role of the 
NO/cGMP/PKG pathway in regulating the apoptosis of VSMCs. Low physiological 
levels of NO are anti-apoptotic, whereas high pathological levels of NO are 
pro-apoptotic. Both anti-apoptotic and pro-apoptotic effects appear to be mediated by 
the cGMP/PKG signaling pathway, however, they likely involve very different levels 
of activation of PKG (or, more likely, different isoforms of PKG, as discussed below). 
51 
Furthermore, activation of pGC and elevation of cGMP levels induced by 
pretreatment with ANP causes significant protection against the pro-apoptotic effects 
of NO, again showing the presence of an anti-apoptotic/cytoprotective pathway 
involving cGMR Using the unique, specific PKG inhibitors DT-2 and DT-3, basal 
PKG activity was found to play an important role in protecting VSMCs against 
serum-deprivation-induced apoptosis or high-level-NO-induced apoptosis. 
The anti-apoptotic and pro-apoptotic effects of the PKG pathway are likely to be 
mediated by the two different isoforms of PKG, i.e. PKG-Ia mediating the 
anti-apoptotic effects and PKG-Ip mediating the pro-apoptotic effects. This idea is 
based on the observations that almost all of the mammalian cells studied to date in 
our laboratory (e.g. neural cells, immortalized uterine epithelial cells, ovarian cancer 
cells and pancreatic islets) display the anti-apoptotic effects of basal (or low-level) 
PKG activity and all of these cells express the PKG-Ia isoform of PKG. Only one of 
the cell types listed above, the pancreatic islets, expresses the second isoform of 
PKG-I, i.e. PKG-ip, like observed in VSMCs, and only the pancreatic islets display 
the pro-apoptotic effects during high-level stimulation of the cGMP/PKG pathway, 
suggesting that PKG-ip may be involved in the pro-apoptotic effects. Furthermore, 
colon cancer cells, which were shown to have pro-apoptotic effects upon stimulation 
of the PKG activity, express only the PKG- ip isoform (Deguchi et al, 2004). The 
5 2 
PKG-I gene encodes for two isoforms, PKG-Ia and PKG-ip, which differ only in the 
first 100 amino acids of the N-terminal. This region of the PKG-I molecule is known 
to mediate the binding of the enzyme to different target proteins within mammalian 
cells. Thus, it is reasonable that PKG-Ia and PKG-ip will be localized within 
different regions of mammalian cells and would phosphorylate completely different 
sets of downstream target proteins. This could result in different responses, perhaps 
even opposite responses, being initiated by the two PKG-I isoforms. Both isoforms 
of PKG-I are expressed in VSMCs (Casteel et al., 2005). 
The model in Figure 4.12 shows the proposed role of the two different isoforms 
of PKG-I on the regulation of apoptosis in mammalian cells that express both 
PKG-Ia and PKG-ip. PKG-Ia, which has a Kact for cGMP of approximately 0.1 
would be partially activated by intracellular cGMP at basal levels (estimated to be 
0.05 - 0.1 \iM). This would provide an anti-apoptotic/cytoprotective effect even at 
basal cGMP levels during normal culturing conditions. In contrast, PKG-ip, which 
has a Kact for cGMP of 0.5 - 1 |_iM，would be activated only when intracellular levels 
of cGMP are substantially elevated. Conditions that would result in large increases in 
cGMP levels and activation of the PKG-ip isoform would include severe 
inflammation, ischemia and trauma, which are known to generate high levels of NO. 
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Figure 4.12. Model showing anti-apoptotic and pro-apoptotic effects of the PKG 
pathway, mediated by two different isoforms of PKG, PKG-Ia and PKG-ip. 
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Chapter 5. Role of protein kinase G (PKG) in regulation of 
proliferation in VSMCs 
5.1 Introduction 
VSMCs acquire altered phenotypes in response to vessel growth, vascular injury 
and, in the case of rat VSMCs, even during in vitro culturing of these cells 
(Chamley-Campbell et al.，1979; Chamley-Campbell et al , 1981; Campbell et al., 
1985; Gown et al., 1986; Mosse et al., 1985; Owens, 1995). In contrast to the normal 
development of smooth muscle cells from relatively dedifferentiated precursor cells 
to mature, differentiated contractile cells, the abnormal modulation of mature 
VSMCs from a contractile phenotype and a synthetic phenotypes is thought to be a 
response to injury of the vessel wall (Sapino et al., 1990; Majesky et al., 1992). 
The NO/cGMP/PKG pathway is thought to controls this modulation of 
phenotype in VSMCs (Lincoln et al., 2001). When rat VSMCs begin to change their 
phenotype during culturing, the expression levels of PKG are dramatically reduced, 
suggesting that the decrease in PKG gene expression may have been a prerequisite 
for phenotypic modulation. Interestingly, when PKG was re-introduced (at high 
levels) back into the VSMCs by transfecting the cells to overexpress PKQ the 
phenotypically-modulated rat VSMCs reverted back to their original contractile 
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(normal) phenotype (Brothy et al., 2001). Because several vascular disorders are 
related to the accumulation of synthetic, fibroproliferative VSMC in the vessel wall, 
it is likely that changes in the activity of the NO/cGMP/PKG pathway is involved the 
development of these diseases. 
In contrast to rat VSMCs, cultured VSMCs isolated from certain other species, 
such as human, bovine and rabbit, maintain the levels of PKG expression during 
multiple passaging. In rat and mouse VSMCs, PKG expression levels fall to 
undetectable levels after only a few passages. The mechanism responsible for this 
decrease in PKG expression is still unknown. High cell density appears to increase, 
or at least maintain, higher expression levels in cultured rat VSMCs (Comwell et al , 
1994). Serum-derived growth factors such as platelet-derived growth factor may 
reduce PKG expression in vitro, suggesting that withdrawal of growth factors may 
help to maintain normal levels of PKG expression in VSMCs (Tamura et al., 1996). 
For many years it has been generally thought that the stimulation of the 
cGMP/PKG pathway causes anti-proliferative effects in VSMCs and that this 
response is involved in the NO-induced inhibition of atherogenesis (Lincoln et al , 
2001). However, recent data from transgenic mice, PKG-knock-out and 
PKG-overepressing mice, have suggested that PKG promotes, rather than inhibits, 
the proliferation of VSMCs (Feil et al , 2005). Thus, the role of PKG in regulating 
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VSMC proliferation appears contradictory. 
To our knowledge, there has been no report of using the highly-specific PKG 
inhibitors DT-2 and DT-3 in determining the role of PKG in the regulation of VSMC 
proliferation. The aim of the present study is to determine whether basal PKG 
activity is involved in the inhibition or the stimulation of proliferation in VSMCs, 
using mouse aortic VSMC in passage 0 (i.e. phenotypically normal VSMCs) and 
using the specific inhibitors of PKG, DT-2 and DT-3. 
5 7 
5.2 Results 
Both of the PKG type I isoforms, PKG-Ia and PKG-ip，were expressed in 
freshly isolated mouse aorta and in cultured mouse VSMCs (Figure 5.1). Both 
PKG-Ia and PKG-ip were highly expressed in freshly isolated mouse aorta, but were 
greatly diminished in cultured mouse VSMCs, beginning at passage 0. The 
expression of PKG-Ia appeared to return to levels in freshly isolated aorta, whereas 
PKG-ip continued to become diminished. 
Figure 5.2 shows that inhibition of basal PKG activity using DT-2 (250 nM and 
1000 nM, 72h) significantly (***p<0.001) decreased by 65% and 82%, respectively, 
the rate of cell proliferation stimulated by serum. DT-3 and KT5823 also caused 
significant inhibition of cell proliferation. Figure 5.3 shows the results of other 
experiments using MTT assay to measure cell proliferation rate. The data show that 
inhibition of basal PKG activity with DT-2 (250 nM and 1000 nM) significantly 
(***p<0.001) decreased by 43% and 53%, respectively, the rate of cell proliferation 
stimulated by serum. Similar results were obtained using DT-3. 
In Figure 5.4, a third technique (BrdU incorporation into newly synthesized 
DNA) was used to measure cell proliferation rate. Consistent with the other 
techniques, the BrdU assay showed that DT-2 at 125 nM (***p<0.001), 250 nM 
(***p<0.001) and 1000 nM (*p<0.05) significantly decreased the rate of DNA 
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synthesis stimulated by serum (over 4 h). Similar results were obtained with the other 
PKG inhibitor, DT-3. 
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Figure 5.1 Western Blot showing the expression levels of PKG isoforms in fleshly 
isolated rat aorta (RA), freshly isolated mouse aorta (MA) and cultured mouse 
VSMCs, passages 0, 1 and 2 (PO, PI and P2). Although Panel A and Panel B show 
similar results, Panel B shows a more clear separation of the two isoforms of PKG. 
High levels of PKG-Ia and PKG-ip were expressed in freshly isolated aortas from 
both rat (Panels A and B) and mouse (Panel A). The levels of expression of both 
PKG-Ia and PKG-ip were diminished in cultured mouse VSMCs, beginning at 
passage 0. However, PKG-Ia expression appeared to recover to levels almost as high 
as in freshly isolated aorta by P2. PKG-ip expression levels continued to become 
diminished. 
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Figure 5.2 Measurement of cell proliferation using cell count technique. Inhibition of 
basal PKG activity in the mouse VSMCs (passage 0) using DT-2 (250 nM and 1000 
nM, 721i) significantly (***p<0.001) decreased by 65% and 82%, respectively, the 
rate of cell proliferation stimulated by serum. Similar results were obtained for DT-3 
and KT-5823. DT-3 (250 nM and 1000 nM, 72h) decreased by 46% and 69%, 
respectively, and KT-5823 (250 nM and 1000 nM, 72h) significantly (*p<0.05 and 
***p<0.001) decreased by 39% and 56%, respectively, the rate of cell proliferation. 
The data represent the mean 土 SEM of four observations per treatment group. 
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Figure 5.3 Measurement of cell proliferation rates using the MTT assay. Panel A 
shows that inhibition of basal PKG activity by DT-2 (250 nM and 1000 nM, 72h) 
significantly (***p<0.001) decreased by 43% and 53%, respectively, the rate of cell 
proliferation stimulated by serum. Similar results were obtained using DT-3 at 250 
nM (*p<0.05) and 1000 nM (***p<0.001)，whcih significantly decreased the rate of 
cell proliferation stimulated by serum by 33% and 65%, respectively. Panel B shows 
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the data presented as increase in the number of cells (data converted from absorbance 
units obtained in the MTT assay into number of cells). Firstly, a standard curve in the 
MTT assay was generated using absorbance versus a range of number of cells. Then 
the absorbance from the MTT assay could be converted back to the number of cells. 
The data from Panel B shows similar results as the cell count study shown in Figure 
5.2. The data represent the mean 士 SEM of four observations per treatment group. 
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Figure 5.4 Measurement of de novo DNA synthesis using an ELISA that quanifies 
the levels of BrdU incorporation. Panel A. Inhibition of basal PKG activity using 
DT-2 at 125 nM (***p<0.001), 250 nM (***p<0.001) and 1000 nM (*p<0.05) 
significantly decreased DNA synthesis rate in VSMCs stimulated by serum (for 4 h). 
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Panel B shows similar results using DT-3 at 125 nM, 250nM and 1000 nM. The data 
represent the mean 士 SEM of four observations per treatment group. 
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Proposed model of the growth-promoting effects of PKG-Ia 
effects of PKG-ip in VSMCs 
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5.3 Discussion 
Most of the previous experiments studying the role of the cGMP/PKG pathway 
in VSMC proliferation have concluded that cGMP/PKG has anti-proliferative effects 
and have proposed that this response may be involved in the effects of NO in 
preventing development of atherosclerosis (Lincoln et al.，2001). 
The role of NO/cGMP/PKG pathway in the regulation of VSMC proliferation is 
still not clear. It has been demonstrated that high concentrations of NO donor drugs 
decrease the mRNA levels for PKG-Ia in primary cultures of bovine VSMCs (Soff et 
al., 1996). High concentrations of NO have also been shown to inhibit VSMC 
growth in vitro (Ignarro et al., 2001), and it has been suggested that the p42/p44 
mitogen-activated protein kinase (MAPK) pathway and induction of p21(wafl/cipl) 
were involved in the anti-proliferative effects of NO in rat VSMCs (Bauer et al, 
2001). Various other studies have reported that NO/cGMP inhibits VSMC 
proliferation (Sarkar et al., 1998; Koyama et al., 2001). Moreover, it has been 
reported that cGMP-elevating reagents suppress smooth muscle cell proliferation via 
the activation of PKG and the phosphorylation and inhibition of Raf-1 (Yu et al., 
1997). In contrast, cGMP and low concentrations of NO has been reported to 
stimulate the growth of primary VSMCs (Hassid et al , 1994; Wolfsgruber et al., 
2003), although the mechanism of these responses were not clear. More recently, in 
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PKG-knockout mice, the growth promoting effect of cGMP was found to be absent 
(Wolfsgruber et al., 2003). It has also been reported that primary VSMCs of the 
smooth muscle-specific PKG-knockout mice showed an impaired development of 
VSMC-derived plaque cells and a significantly decrease in the lesion area 
(Wolfsgruber et al., 2003)，suggesting that PKG expression was required for normal 
growth of vascular cells and for angiogenesis. 
Although the role of PKG in regulating VSMC proliferation is still unclear, it 
has been reported that PKG activity is critical for smooth muscle cells to retain the 
contractile-like phenotype (Boerth et al., 1997). Rat VSMCs grown in culture over 
several passages are known to have diminished expression levels of PKQ and it has 
been proposed that this PKG diminution is an essential player in the mechanism 
leading to phenotypic modulation. Indeed, overexpression on PKG using transfection 
in these synthetic phenotype VSMCs resulted in the cells acquiring a more 
contractile phenotype (Brophy et al , 2001). Interestingly, serum-derived growth 
factors, such as platelet-derived growth factor, have been shown to reduce PKG 
expression in cultured VSMCs (Tamura et al.，1996). 
None of the previous reports, however, have been able to distinguish the 
changes in expression of the different PKG isoforms (type l a and 1(3) during 
passaging. In the present study, Western blot analysis (Figure 5.1) was used to 
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determine expression levels of the different PKG isoforms during passaging of 
mouse aortic VSMCs. The data show that high levels of both PKG-Ia and 
PKG-ip are expressed in freshly isolated mouse aorta, but both isoforms of PKG are 
diminished in cultured mouse VSMCs, beginning at passage 0. PKG-Ia levels 
appeared to return of near normal levels by passage 2，whereas PKG-ip continues to 
become diminished Hence, PKG-Ia may be the form of PKG that is necessary for 
stimulation of cell proliferation. PKG-Ia levels seemed to increase in expression 
levels just as the VSMCs become more synthetic and fibroblastic in later passages. 
Consistent with the recent findings, the present study shows that basal PKG 
activity mediates the stimulation of proliferation by serum in cultured VSMCs. Cell 
count study (Figure 5.2) shows that PKG inhibitors, DT-2, DR-3 and KT5823, 
dose-dependently inhibit serum-induced proliferation in primary cultured (passage 0) 
VSMCs over 3 days. 
Similar results were obtained with the MTT assay, which is designed for the 
spectrophotometric quantification of cell growth and viability (Figure 5.3). Inhibition 
of basal PKG activity using DT-2 and DT-3 signficantly inhibited cell growth, as 
assessed by the MTT assay. 
The results were further confirmeds using a colorimetric BrdU cell proliferation 
ELISA assay (Figure 5.4). This colorimetric immunoassay is designed to quantify 
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cell proliferation based on the measurement of BrdU incorporation during DNA 
synthesis in proliferating cells. Inhibition of basal PKG activity by DT-2 or DT-3 
significantly decreased the rate of DNA synthesis stimulated by serum over 4 h. 
The PKG gene encodes two isoforms, PKG-Ia and PKG-Ip, which differ in 
their N-termini for about 100 amino acids that mediate binding to different target 
proteins. Both isoforms are expressed in VSMCs (Casteel et al., 2005). The PKG 
isoforms l a and 1(3 are present in VSMCs, lung, cerebellum, platelets, and heart 
(Francis et al., 1994; Keilback et al., 1992). However, the specific role of each PKG 
type I isoform is still unknown. We hypothesized that the anti-proliferative and 
pro-proliferative effects of the PKG pathway are mediated by two different isoforms 
of PKG, i.e. PKG-Ia mediating the pro-proliferative effects and PKG-Ip mediating 
the anti-proliferative effects, based on observations that some transformed neural 
cells (e.g. NG108-15 and PC 12 cells) and immortalized uterine epithelial cells 
express the PKG-Ia isoform. This PKG-Ia isoform is retained within passaging of 
these transformed or immortalized cells, perhaps because PKG-Ia is required for the 
proliferation and survival. PKG-Ia, which has a Kact for cGMP of approximately 0.1 
I^M, would be partially activated by intracellular cGMP at basal levels (e.g. 0.05 -
0.1 f^M), thus providing anti-apoptotic and pro-proliferative effects even during 
normal culture conditions. In contrast, PKG-ip，which has a Kact for cGMP at 0.5 一 1 
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|J.M, would be activated only when intracellular levels of cGMP are substantially 
elevated, like inflammation or trauma. Thus, these results suggest that PKG, likely 
PKG-Ia, plays an important role in mediating serum-factor stimulation of 
proliferation in primary, phenotypically-normal VSMCs. 
Figure 5.5 shows the proposed model of the growth-promoting effects of 
PKG-Ia and growth-inhibiting effects of PKG-ip in VSMCs. Under basal, 
physiological conditions, serum factors stimulate the growth of VSMCs through 1) 
the MAP kinase pathway and 2) the cGMP/PKG pathway (Figure 5.5A). Serum 
factors stimulate low levels of cGMP, which activates PKG-Ia and in turns, promote 
growth of the cells thourgh c-Src (based on unpublished data from our laboratory, not 
included in this thesis). The unpublished data have shown that by using recombinant 
PKG-la and human c-Src in vitro, c-Src tyrosine-phosphorylates PKG-la (Western 
blot, PY20 antibody). In addition, the autophosphorylation (i.e. activation) of c-Src 
was enhance by PKG-lo; suggesting that PKG serine-phosphorylates c-Src, 
enhancing the Src tyrosine kinase activity. Moreover, it has been shown that Src can 
stimulate ERK. Thus, under normal physiological condition, basal cGMP and 
PKG-la may regulate VSMC proliferation through c-Src, ERK and MAP kinase 
pathway. In contrast, when there is severe inflammation, producing high levels of 
NO, there will be large increases in cGMP levels (Figure 5.5B). This much higher 
7 1 
level of cGMP can activate the PKG-ip isoform and through alternate downstream 
proteins, like p-catenin, may inhibit the growth of VSMCs. 
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Chapter 6. Effects of aging and eNOS- and iNOS-gene deletion 
(using eNOS- and iNOS-knockout mice) on apoptosis of vascular 
smooth muscle cells 
6.1 Introduction 
NO is synthesized from the amino acid L-arginine by 3 forms of nitric oxide 
synthases (NOS), the neuronal form of NO synthase (nNOS/ type I-NOS), the 
inducible form of NO synthase (iNOS/ type II-NOS) or the endothelial form of NOS 
(eNOS/ type III-NOS) (Moncada and Higgs, 1993; Forstermann et al., 1995). In the 
circulatory system, NO acts as a local tissue regulator inside blood vessels to cause 
smooth muscles relaxation and vessel dilation (Vanhoutte et al., 1995). In the 
immune system, NO produced by macrophages and other immune cells helps to kill 
invading bacteria and viruses (Bogdan, 1997). In central nervous system (CNS) and 
peripheral nervous system (PNS), NO acts as a neurotransmitter in certain neurons 
(Garthwaite, 1995). 
Aging is associated with the development of cardiovascular structural and 
functional alterations, which can explain the age-related increase in cardiovascular 
risk (Kannel et al., 1976). Advancing age is associated with endothelial dysfunction 
in both normotensive subjects and essential hypertensive patients, an alteration 
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caused by a progressive impairment of the NO pathway and production of oxidative 
stress (Taddei et al., 2006). Since NO plays a critical role in the maintenance of blood 
pressure homeostasis (Ress et al , 1989)，alterations in NO synthesis may be related 
to the pathogenesis of hypertension 
The role of NO in the development of apoptotic events is crucial to understand 
all the phenomena related to vascular remodeling and the maintenance of the 
architecture of the vessels (Hamet et al., 1996). Numerous reports have investigated 
the effect of iNOS- (Sam et al., 2001; Yang et al., 2004) and eNOS-knockout mice 
(Yang et al , 1999; Liu et al , 2002; Barouch et al., 2003; Li et al, 2004; Ruetten et 
al., 2005) on age-related cardiac dysfunction. Although endothelial cells are by far 
the main site of vascular NO synthesis, VSMCs do express iNOS (Luoma et al., 1998) 
and eNOS (Pandofil et al., 2003) under certain conditions. However, limited work 
has been done in investigating the role of NOSs in VSMCs apoptosis. Vascular 
responses of aorta from iNOS have been studied (Nangle et al., 2003). Transfection 
of iNOS gene causes apoptosis in vascular smooth muscle cells (Iwashina et al, 
1998). Human macrophage-induced VSMC apoptosis requires NO enhancement of 
Fas/Fas-L interactions (Boyle et al., 2002). Decreased eNOS activity and expression 
and increased iNOS expression has been reported in aortas of aged rats (Chou et al., 
1998). 
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As discussed in Chapter 4’ NO plays a dual role in apoptosis, depending on the 
type of cells, and the level of activation. Low-level stimulation of the cGMP/PKG 
pathway may have anti-apoptotic effects, whereas high-level stimulation of the 
cGMP/PKG pathway may have pro-apoptotic effects in the VSMCs. Therefore, 
investigating the effects of aging and role ofNOS in VSMCs apoptosis would further 
complete the picture. 
The present study determines whether aging and/or gene deletion of specific 
NOS gene can alter the rate of spontaneous apoptosis occurring in isolated VSMCs. 
Aortic VSMCs from eNOS- and iNOS-knockout mice, both young and aged mice, 
were used. The levels PKG expression were measured by Western blot analysis and 
the levels of spontaneous apoptosis were determined by Cell Death Detection ELISA 
(measuring apoptotic DNA fragmentation). 
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6.2 Results 
Figure 6.1 shows the PKG expression levels in young and aged NOS knockout 
mice. PKG expression was decreased when either iNOS or eNOS was knocked out. 
PKG expression also decreased in aging within all 3 groups, i.e. the C57/BL6 group, 
iNOS-knockout group and eNOS-knockout group. Figure 6.2 shows the level of 
apoptosis in VSMCs from young and aged control and NOS-knockout mice as 
quantified by Cell Death ELISAP^"'. Aging significantly (***p<0.001) increased 
apoptotis in C57/BL6 and iNOS-knockout group, when compared with their young 
ones, respectively. Gene deletion of iNOS and eNOS seemed to have a protective 
effect in aging-induced apoptosis. 
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Figure 6.1 Western blot of PKG expressions in young and aged NOS knockout mice. 
PKG expression was decreased when either iNOS or eNOS was knocked out. PKG 
expression was also decreased in VSMCs from aged mice in all 3 groups, i.e. the 
C57/BL6 group, iNOS-knockout group and eNOS-knockout group. 
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Figure 6.2 Levels of apoptosis in VSMCs from male young and aged control and 
NOS-knockout mice as quantified by Cell Death ELISA^'"'. Aging significantly 
(***p<0.001) increased apoptotis in C57/BL6 and iNOS-knockout group, when 
compared with the young controls, respectively. Gene deletion of iNOS and eNOS 
seemed to have a protective effect in aging-induced apoptosis when compared with 
aged C57/BL6 (#p<0.05 for aged C57/BL6 vs aged iNOS-KO, ###p�0.001 for aged 
C57/BL6 vs aged eNOS-KO). The data represent the mean 士 SEM of four 
observations per treatment group. 
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6.3 Discussion 
Aging, like diabetes mellitus, is thought to cause decreased expression of the 
two constitutive forms o fNOS, eNOS and nNOS, and to upregulate the expression of 
iNOS in the cardiovascular system (Vanhoute et al., 1995) as well as the central and 
peripheral nervous systems (Fiscus, 2002). This can result in diminished production 
of NO in blood vessels, potentially resulting in the increased risk of developing 
hypertension and atherosclerotic lesions. Other members of the NO/sGC/cGMP/PKG 
signaling pathway may also become downregulated during the aging process, 
potentially causing further impairment of vascular function. Furthermore, there may 
be changes in downstream proteins, such as PKG, when the NOS expression levels 
are altered. 
The present study determined whether aging and knockout of the eNOS and 
iNOS genes can change in the expression levels of PKG in mouse aortic VSMCs. 
Furthermore, the effects on spontaneous apoptosis of aging and eNOS or iNOS gene 
deletion were determined. The present data show that PKG was expressed in the 
VSMCs of all young and aged control and NOS-knockout mice. However, the PKG 
expression levels were decreased when either iNOS or eNOS was knocked out. PKG 
expression levels were also decreased in all of the aged groups, i.e. the C57/BL6 
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group, iNOS-knockout group and eNOS-knockout group. 
The data suggest that aging diminishes the expression of PKG in VSMCs, 
which may contribute to further impairment of the vascular responses in the elderly. 
Aging also caused elevated levels of spontaneous apoptosis in VSMCs (maintained 
in primary culture). It is tempting to speculate that the aging-related downregulation 
of PKG may have increased the susceptibility of the cells to the onset of apoptosis. 
This idea would be consistent with the data of Chapter 4. However, in the VSMCs of 
eNOS-knockout mice, the levels of spontaneous apoptosis were not elevated, even 
though PKG expression levels were greatly diminished. Further studies will be need 
to elucidate the relationship between eNOS expression, PKG expression and the 
protection against spontaneous onset of apoptosis. 
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Chapter 7. Role of protein kinase G in regulation of apoptosis and 
proliferation of bone marrow stromal stem cells 
7.1 Introduction 
Stem cell research has been widely accepted to be a future therapy for treating 
various genetic and metabolic diseases. A stem cell is traditionally defined as a cell 
that is capable of self-renewing and differentiating into an unlimited number of 
different cell types (Weissman, 2000). Cell transplantation is one potential therapy to 
tissue regeneration and repair. In the clinical arena, stem cells are now being 
examined in the lungs and tested in improving vascularisation and repairing 
myocardium (Sanders et al., 2006). Approaches involving experimental cell 
transplantation to restore functional myocardium have been reported and include the 
use of skeletal myoblasts, fetal cardiomyocytes (CM), neonatal CM, adult CM, atrial 
tumor cell lines, cardiac stem cells, bone marrow stem cells, neuronal stem cells, 
endothelial stem cells, hepatocyte stem cells, and embryonic stem (ES) cells (Dowell 
et a l , 2003). A model of stem cell growth and differentiation is presented in Figure 
7.1. 
Stem cell research has been an exceptionally active area in medical research in 
recent years. Controlling the NO/cGMP/PKG signaling pathway in stem cell cultures 
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may be a way to affect the activation or differentiation of these cells, and may be a 
way to improve the transplantation of stem cells for therapeutic purposes. For 
example, mouse ES cells can be accelerated to differentiate into CM by NO 
treatment (Kanno et al., 2004). NO donors were shown to inhibit erythroid but 
enhance myeloid colony formation from isolated CD34+ bone marrow-derived cells 
(Shami et al., 1996). Also, NOS inhibitors were used to examine hematopoietic stem 
cell activity in vivo in mice (Michurina et al., 2004). Interestingly, treatment of 
animals with NOS inhibitors increased the number of stem cells in the bone marrow 
(Michurina et al., 2004). Furthermore, mobilization of bone marrow stem and 
progenitor cells was shown to be impaired in eNOS knockout mice, which appeared 
to be related to impaired neovascularization (Aicher et al , 2003). 
It has also been reported that hematopoietic stem cells could be used to produce 
endothelial progenitor cells, which could revascularize injured tissues (Guthrie et al, 
2005). Induction of NOS is involved in the mechanism of Fas-mediated apoptosis in 
haemopoietic cells (Selleri et al., 1997). However, there are very few studies on the 
role of cGMP/PKG pathway in stem cells (Krumenacker AND Murad, 2005). Only 
until very recently, expression of mRNA and protein levels of the three NOSs and 
sGC has been reported in mouse ES cells and ES cell-derived cardiomyocytes 
(Krumenacker et a l , 2006). They have also reported that PKG protein expression 
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increases in differentiation. However, there has been no information regarding the 
expression of PKG l a and Ip isoforms in stem cells. 
In the present study, stromal stem cells from adult rat bone marrow were used 
and the role of PKG in apoptosis and proliferation was studied. PKG lo t and ip 
protein expression were investigated by Western blot analysis. The specific PKG 
inhibitors DT-2 and DT-3 were used to inhibit basal PKG activity to investigate the 
role of PKG in apoptosis and proliferation in the stromal stem cells. 
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7.2 Results 
Figure 7.2 shows a picture of the rat bone marrow stromal stem cells. Figure 7.3 
shows the Western blot of the stem cells, illustrating the expression of the PKG 
isoforms. Both PKG-Ia and PKG-ip were highly expressed in these cells. 
Cell count study showed a decrease in cell proliferation when basal PKG 
activity was inhibited by DT-2 or DT-3, similar to the results with VSMCs, shown in 
Chapter 5. Figure 7.4 shows the serum-induced increase in number of stem cells 
(passage 19) over 3 days. DT-2 (250 nM and 1000 nM, 72h) significantly (*p<0.05 
and ***p<0.001) decreased by 56% and 67%, respectively, the rate of cell 
proliferation stimulated by serum. Similarly, DT-3 at 1000 nM decreased the rate of 
cell proliferation by 60% (*p<0.05). 
Figure 7.5 shows the levels of apoptosis as quantified by Cell Death Detection 
ELISA in the stem cells (passage 21) treated with DT-2 for 72 h. Inhibition of basal 
PKG activity had no effect on apoptotic levels in the presence (+S) or absence (-S) of 
serum. 
8 4 
Marrow sinuses Marrow stroma 
• * 飄 — — 
Osteoblast Adipocyte Chondrocyte Epithelium Hepatocyte Muscle 
令 令 
Mesenchymal stem cells Hematopoietic stem cells 
6 ‘ 
^ M i Multipotent progenitors 
^ ^ Dendritic c e l l \ \ 
Common myeloid progenitor ' ^ r o c y t T " 
參 % 
Megakaryocytic/ei^hroid precursors Myelomonocytic precursor Common lymphoid progenitor 
© 八 备 藝 食 參 
Erythrocytes Platelets Granulocyte Macrophage Tcell NK cell Bcell 
Figure 7.1 Cross-section of a bone marrow and bone marrow derived stem cells 
(Adapted from Dunsmore and Shapio，2004). 
(a) Cross section of tubular bone showing the structure of bone marrow. 
Hematopoietic spaces are organized into cords by stromal cells (green lines) and 
contain distinct foci of developing erythroid and granulocytic cells interspersed 
among immature hematopoietic precursors. Mature blood cells enter the circulation 
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by migrating across the marrow sinus endothelium. 
(b) Two populations of stem cells may be isolated from bone marrow. Mesenchymal 
stem cells, isolated from marrow stroma, adhere to tissue culture plasticware and 
have been shown to have the potential to differentiate into osteoblasts, adipocytes, 
and chondrocytes. Hematopoietic stem cells, which do not adhere to tissue culture 
plasticware, not only have the capacity to produce mature blood cells but also have 




Figure 7.2 Images of adult rat bone-marrow derived stromal (mesenchymal) stem 
cells in culture under the microscope (phase contrast). The cells are in the 18^  
passage. The cells were spread-out and attached firmly on the surfaces of the plate. 
The morphology of these stem cells is very different from the spindle-shaped 
morphology of the VSMCs used in the other chapters. 
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Figure 7.3 Western blot showing the expression of PKG isoforms in adult rat 
mesenchymal stem cells (rMSCs), also called stromal stem cells. High levels of both 
PKG-Ia and PKG-I(3 were expressed in the rMSCs, similar to levels found in rat and 
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Figure 7.4 Serum-induced increase in the number of rMSCs (passage 19) over 3 days. 
PKG inhibitors DT-2 and DT-3 were added at 25, 125，250 and 1000 nM. Inhibition 
of endogenous PKG activity by DT-2 (250 nM and 1000 nM, 72h) significantly 
(*p<0.05 and ***p<0.001) decreased by 56% and 67%, respectively, the rate of cell 
proliferation stimulated by serum. Similar results were obtained for DT-3. DT-3 at 
1000 nM decreased the rate of cell proliferation by 60% (*p<0.05). The data 
represent the mean 士 SEM of four observations per treatment group. 
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Figure 7.5 Levels of apoptosis as quantified by Cell Death Detection ELISA in 
rMSCs (passage 21) treated with DT-2 for 72 h. DT-2 had no effect on apoptotic 
levels in the presence (+S) or absence (-S) of serum, although withdrawal of serum 
increases apoptosis by 2 or 3 fold. These results suggested that basal PKG activity 
was not essential for preventing apoptosis in these rMSCs when cultured with or 
without serum. The data represent the mean 土 SEM of four observations per 
treatment group. 
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7.3 Discussion 
Rat bone marrow-derived mesenchymal stem cells (rMSCs), also called stromal 
stem cells, were used in the present study. Two populations of stem cells may be 
isolated from the bone marrow, illustrated in Figure 7.1. Mesenchymal stem cells, or 
stromal stem cells, isolated from marrow stroma, adhere to tissue culture plasticware 
and have been shown to have the potential to differentiate into osteoblasts, 
adipocytes, and chondrocytes. Hematopoietic stem cells, which do not adhere to 
tissue culture plasticware, not only have the capacity to produce mature blood cells 
but also have been shown to engraft into liver, lung, kidney, heart, skeletal muscle, 
pancreas, and gastrointestinal tract. 
Both PKG-Ia and PKG-ip isoforms were found to be highly expressed in 
rMSCs. However, unlike the mouse VSMCs (where PKG expression decreases 
gradually during passaging), these adult rMSCs retain high levels of PKG expression 
upon passaging. 
Inhibition of basal PKG activity in rMSCs decreased the rate of cell 
proliferation. Both DT-2 and DT-3 dramatically reduced cell proliferation rates to 
less than half of control levels. The present data suggest that basal activity of PKG 
(likely the PKG-Ia isoform) is essential for normal proliferative responses in rMSCs. 
The level of apoptosis were not affected by inhibition of baaal PKG activity, 
9 2 
either in the presence (+S) or absence (-S) of serum. These results suggested that 
basal PKG activity PKG may not be playing a critical role in preventing spontaneous 
onset of apoptosis in rMSCs. 
Taken together, the present data with the bone marrow stromal stem cells also fit 
with our hypothesis that PKG-Ia promotes growth and PKG-ip inhibits 
growth.. Figure 7.6 shows a model illustrating the potential role of the 
NO/cGMP/PKG pathway and the different isoforms of PKG in mediating the 
growth-promoting and growth-inhibiting effects of this signaling pathway., as 
discussed in Chapter 5. It is proposed that, under basal, physiological conditions, 
serum factors or other stimuli (e.g. low-level NO from eNOS or nNOS) stimulate the 
growth of rMSCs through 1) the MAP kinase pathway and 2) the cGMP/PKG 
pathway (Figure 7.6，Panel A). Serum factors or physiological levels of NO stimulate 
low-level production of cGMP, which causes moderate elevation of PKG-Ia activity 
and promotes growth of the cells potentially through enhancing c-Src 
autophosphoylation (activation). On the other hand, at high levels of NO, such as 
during severe inflammation in high-level iNOS induction, the NO will cause large 
increases in cGMP levels (Figure 7.6 B). This much higher level of cGMP can 
activate the PKG-ip isoform and, through alternate downstream proteins like 
p-catenin, could override the proliferation-stimulating effect of PKG-Ia, thus 
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inhibiting the growth of the stromal stem cells. 
The innovative use of stem cells for vascular tissue engineering has opened new 
possibilities for vascular tissue regeneration. Much new research is needed to 
investigate the molecular mechanisms of stromal stem cell differentiation, 
proliferation and apoptosis, in order to evaluate their full capacity for tissue 
regeneration in the future. 
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Chapter 8. Overall discussion 
The vascular complications of diabetes mellitus involve abnormal (diminished) 
vascular responses to vasodilators, such as the neuropeptide CGRP, and abnormal 
(enhanced) growth of the arterial/arteriolar wall, contributing to macro- and 
micro-vessel abnormalities of diabetes. The abnormal growth likely involves an 
imbalance between apoptosis and proliferation of the VSMCs in the walls of arteries 
and arterioles. In normal arteries, CGRP-induced vasodilations are known to involve 
activation of the cAMP pathway in VSMCs. Diabetic abnormalities could result from 
an mpairment of the cAMP response to CGRP. However, this has not been reported 
until now. 
The present study shows that cAMP responses to CGRP are significantly 
diminished in VSMCs following 6 h exposure to high glucose levels. Potentially, this 
impairment could be responsible for the damaged vascular responses to CGRP 
observed in diabetic animals. Because CGRP is recognized to be an important factor 
in preventing hypertension and causing vasodilation in response to inflammatory 
mediators, the impairment in cAMP response to CGRP during hyperglycemia may 
contribute to the hypertension and abnormal inflammatory responses often observed 
in diabetic patients. 
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Regulation of apoptosis and proliferation in VSMCs is thought to involve, at 
least in part, the cGMP/PKG signaling pathway. However, previous reports 
concerning the role of cGMP/PKG in VSMC apoptosis and proliferation are 
contradictory and incomplete. Furthermore, almost all of the previous reports had 
used VSMCs grown in culture for many passages, which likely resulted in 
phenotypic modulation (i.e. change in the cell phenotype from normal "contractile" 
(smooth muscle) type to the abnormal "synthetic" (fibroblast-like) type as a result of 
r 
the culturing conditions). Thus, previous data about the role of cGMP/PKG in the 
regulation of apoptosis and proliferation may not be representative of this pathway's 
role in normal VSMCs. 
Previous studies from our laboratory had shown that inhibition of cGMP 
synthesis, using the sGC inhibitor ODQ, causes cellular depletion of cGMP and 
induction of apoptosis in many types of cells, including neural, pancreatic islets, 
ovarian cancer cells and uterine epithelial cell (all under normal culturing conditions 
with 10% fetal bovine serum). The previous data suggested that cGMP, at normal 
basal levels, is essential for preventing spontaneous onset of apoptosis in these cells. 
In the present study, the VSMCs did not show apoptotic responses to ODQ at 
concentrations up to 80 \xM. Furthermore, inhibition of basal PKG activity using 
DT-2 and DT-3, two newly-developed highly-specific inhibitors of PKG, did not alter 
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apoptosis in VSMCs (with serum). However, during serum deprivation DT-2 and 
DT-3 were able to alter apoptosis (significantly enhancing the 
serum-deprivation-induced apoptosis). The data suggest that in VSMCs, unlike in 
many other types of cells, basal activation of the cGMP/PKG pathway is not 
involved in preventing spontaneous apoptosis under normal culturing conditions. 
Only during a stressful condition, such as serum deprivation, was the anti-apoptotic 
(partially protective) effects of PKG observed. 
To further test the idea that PKG protects VSMCs during stress, VSMCs were 
exposed to the NO donor SNAP at high concentration (1 mM)，which would cause 
oxidative/nitrosative stress and ultimately cause apoptosis. When VSMCs were first 
pre-incubated with the natriuretic peptide ANP to elevate cGMP levels and stimulate 
PKG activity prior to SNAP exposure, the SNAP-induced apoptosis was completely 
prevented. The data suggest that, under certain stressful conditions, PKG does have a 
protective role, helping to limit the extent of stress-induced apoptosis in VSMCs. 
Most previous reports have shown that stimulation of PKG (by elevating cGMP 
levels) causes inhibition of VSMC proliferation. However, these previous studies 
were conducted using VSMCs that had been grown for many passages, likely after 
the cells had changed their phenotypes into non-smooth muscle cells. In the present 
study, VSMCs were used before passaging (i.e. passage 0) and the involvement of 
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basal PKG activity on proliferation rate was determined by using the two specific 
PKG inhibitors DT-2 and DT-3. Proliferation rates were measured by three 
techniques: 1) increase in number of cells after 3 days in culture, 2) MTT 
measurement after 3 days in culture, and 3) BrdU incorporation (i.e. de novo 
synthesis of DNA) over 4 hours. All measurements were made using cells that were 
growing under optimal conditions (in 10% FBS, the mitogenic stimulant). Both DT-2 
and DT-3 dramatically reduced proliferation rates (cell count and MTT 
measurements) to only 30% of control rates and reduced de novo DNA synthesis 
rates (BrdU measurement) to half of control levels. The data suggest that basal PKG 
activity is necessary for serum-factor-induced stimulation of cell proliferation in 
phenotypically-normal VSMCs. 
At first glance, the present data, showing an essential role of PKG in the 
stimulation of VSMC proliferation, appear opposite to the anti-proliferative effects of 
PKG reported previously. One possible difference could be the different phenotypes 
of the cells used, i.e. unpassaged VSMCs in the present study versus highly-passaged 
(phenotypically-modulated) VSMCs in previous reports. Another reason for the 
different may involve differential activation of the two isoforms of PKG. For 
example, PKG-Ia, which has a Kact for cGMP-stimulated activation equal to 
approximately 0.1 |iM cGMP, would be partially activated (likely 20-50% activated) 
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by cGMP at normal basal concentrations (typically 0.05 - 0 . 1 |LIM) within VSMCs. In 
contrast, PKG-Ip, which has a Kact that is 10-fold higher (i.e. approximately 1.0 |_iM)， 
would likely not be activated under basal condition, but would be activated only 
when cGMP levels are greatly elevated (e.g. exposure to high levels of NO). Thus, 
under the normal growing conditions of the present study, only PKG-Ia would be 
activated and, therefore, it is this isoform of PKG that would be contributing to the 
enhancement of proliferation in VSMCs. The anti-proliferative effects, observed in 
previous reports using cGMP-stimulating agents, likely involved activation of 
PKG-Ip. Recent studies have shown that PKG-Ia and PKG-Ip localize to very 
different sites within mammalian cells, which would result in phosphorylation of 
completely different sets of downstream substrate proteins in intact cells, potentially 
causing different (and even opposite) effects. Very recent data from Professor Franz 
Hofmann's laboratory in Germany, using PKG-knockout mice, have suggested that 
PKG-Ia is indeed essential for normal VSMC proliferation in culture and for normal 
angiogenesis in vivo, thus complementing the data of the present study. 
In bone marrow stromal stem cells, inhibition of basal PKG activity using DT-2 
or DT-3 did not affect apoptosis, either with or without serum. Thus, PKG may not 
be playing a critical role in preventing spontaneous onset of apoptosis in these cells. 
However, both DT-2 and DT-3 dramatic reduced cell proliferation rate to less than 
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half of control levels. The present data suggest that basal activity of PKG (likely the 
PKG-Ia isoform) is essential for normal proliferative responses in bone marrow 
stromal stem cells. 
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